Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera director Rowan E. Chapman received equity compensation for board service. On 01/30/2026, Chapman was awarded 97 restricted stock units (RSUs) in lieu of a quarterly cash retainer of $23,125 for serving on Natera’s Board of Directors. The RSUs were fully vested at issuance, and each RSU represents one share of Natera common stock. Following this grant, Chapman directly beneficially owned 5,874 shares of Natera common stock.
Natera, Inc. director Roelof Botha received equity compensation for board service. On January 30, 2026, he was issued 112 Restricted Stock Units (RSUs) in lieu of a quarterly cash retainer of $26,875 for serving on Natera's Board of Directors. The RSUs were fully vested at issuance, and each RSU represents a right to receive one share of Natera common stock. Following this grant, Botha directly beneficially owned 2,540 shares of Natera common stock and indirectly beneficially owned 1,154,198 shares through estate planning vehicles.
Natera director Monica Bertagnolli received equity compensation instead of cash fees. On 01/30/2026 she was issued 70 Restricted Stock Units (RSUs) in lieu of a quarterly board retainer of $16,875. The RSUs were fully vested at issuance and each RSU equals one share of Natera common stock, bringing her directly held beneficial ownership to 5,291 shares.
Natera, Inc. director equity compensation filing: Director Roy D. Baynes received 70 shares of Natera common stock on 01/30/2026, reported as an acquisition under code "A". These shares were issued as Restricted Stock Units in lieu of a quarterly board retainer of $16,875.
The RSUs were fully vested at the time of issuance, and each RSU represents a right to receive one share of Natera common stock. Following this award, Baynes beneficially owns 18,429 shares of Natera common stock, held in direct ownership.
An affiliate of the issuer, Michael Brophy, filed a Form 144 notice to sell 5,671 shares of common stock through Morgan Stanley Smith Barney on NASDAQ. These shares were acquired as restricted stock units on 09/28/2025, when payment was recorded as non-cash (N/A).
The filing notes that 138,014,465 common shares were outstanding and lists several sales during the prior three months, including transactions under a Rule 10b5-1 sales plan and direct sales, with individual trades as large as 36,573 and 23,948 shares of common stock.
An insider associated with ticker NTRA has filed a Form 144 indicating an intent to sell up to 85,299 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $19,679,798.82 on the NASDAQ. The notice shows these shares were acquired as restricted stock and performance shares from the issuer in 2022 and 2026. It also lists multiple prior sales of common shares over the past three months by Steven L. Chapman, each with specified dates, share amounts, and gross proceeds, as required under Rule 144 disclosure rules.
Natera insider Solomon Moshkevich has filed to sell 3,000 shares of common stock. The planned sale, through Morgan Stanley Smith Barney LLC on NASDAQ, has an aggregate market value of $694,309.20. The approximate sale date indicated is February 2, 2026.
The 3,000 shares were acquired on January 14, 2026 as performance shares from the issuer. The notice also lists multiple prior sales of Natera common stock over the past three months, including 23,205 shares sold on January 20, 2026 for $5,447,104.57. Natera had 138,014,465 shares of common stock outstanding.
Natera, Inc. CEO and president Steven Leonard Chapman reported two small insider sales of common stock that were tied to restricted stock unit (RSU) vesting and related tax obligations. On January 27, 2026, he sold 2,322 shares at $240.5313, leaving 216,828 shares directly owned. On January 28, 2026, he sold 3,648 shares at $237.6624, leaving 213,180 shares directly owned. Both sales were executed under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions and were made to cover tax withholding and remittance obligations from RSU vesting.
Natera, Inc.’s chief financial officer Michael Burkes Brophy reported multiple sales of common stock on January 27–29, 2026. He sold blocks of 784, 1,237, 1,176, 991 and 876 shares at prices around $240–$230 per share. Footnotes state that part of the sales satisfied tax withholding obligations tied to vesting restricted stock units and relied on written instructions intended to qualify under Rule 10b5-1(c). Other sales were executed under a Rule 10b5-1 trading plan adopted on June 9, 2025 and modified on September 10, 2025. After these transactions, he directly held 59,059 common shares.
Natera, Inc. director and co-founder Sheena Jonathan reported small stock sales mainly to cover taxes on vesting RSUs. On January 27, 2026, she sold 291 shares of common stock at $240.5313 per share. On January 28, 2026, she sold an additional 191 shares at $237.6624 per share. After these transactions, she directly owned 263,596 shares of Natera common stock and indirectly held 21,782 shares in each of the Caraluna 1 Trust and Caraluna 2 Trust. The filing explains that both sales were executed to satisfy tax withholding and remittance obligations related to RSU vesting and were made under written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions.